mesoderm specific transcript pseudogene 3Genealiases: []
Q-omics provides the consensus-scored MESTP3 profile across patient tissues and cancer cell-line models. MESTP3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MESTP3 is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, MESTP3 RNA expression shows 12,184 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, BLCA, and TGCT as cancer lineages where MESTP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MESTP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MESTP3 survival associations across molecular data types. MESTP3 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MESTP3 RNA expression–survival associations across cancer types. High MESTP3 expression shows unfavorable associations in KIRC, CESC, ACC and LGG, but favorable associations in READ and LAML. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MESTP3 RNA expression.
This table summarizes MESTP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for MESTP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MESTP3 shows lower tumor expression in KIRC and BRCA and higher tumor expression in BLCA, COAD, STAD and HNSC. The BLCA box plot shows higher MESTP3 RNA expression in tumor versus normal tissue (log2 FC = +0.199, t-test p = .003).
This table shows molecular features associated with MESTP3 in patient tissues and cancer cell lines. In patient samples, MESTP3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
